Published in Allergy on June 06, 2013
Treatment of allergic rhinitis and urticaria: a review of the newest antihistamine drug bilastine. Ther Clin Risk Manag (2016) 0.97
Comparative efficacy of non-sedating antihistamine updosing in patients with chronic urticaria. World Allergy Organ J (2014) 0.94
Bilastine: new insight into antihistamine treatment. Clin Mol Allergy (2015) 0.82
Bilastine in allergic rhinoconjunctivitis and urticaria: a practical approach to treatment decisions based on queries received by the medical information department. Drugs Context (2017) 0.75
The role and choice criteria of antihistamines in allergy management - expert opinion. Postepy Dermatol Alergol (2016) 0.75
Balanced discussion of second-generation antihistamines' data. Ther Clin Risk Manag (2016) 0.75
Management of urticaria: not too complicated, not too simple. Clin Exp Allergy (2015) 0.75
Effectiveness and safety of antihistamines up to fourfold or higher in treatment of chronic spontaneous urticaria. Clin Transl Allergy (2017) 0.75
Comparative efficacy of bilastine, levocetirizine and desloratadine updosing in chronic urticaria. Ther Clin Risk Manag (2016) 0.75
Updosing of Nonsedating Anti-histamines in Recalcitrant Chronic Urticaria. Indian J Dermatol (2016) 0.75
Review of Physical Urticarias and Testing Methods. Curr Allergy Asthma Rep (2017) 0.75
EAACI/GA(2)LEN/EDF/WAO guideline: definition, classification and diagnosis of urticaria. Allergy (2009) 4.10
EAACI/GA(2)LEN/EDF/WAO guideline: management of urticaria. Allergy (2009) 3.86
High-dose desloratadine decreases wheal volume and improves cold provocation thresholds compared with standard-dose treatment in patients with acquired cold urticaria: a randomized, placebo-controlled, crossover study. J Allergy Clin Immunol (2009) 1.98
Desloratadine inhibits human skin mast cell activation and histamine release. J Invest Dermatol (2009) 1.51
Peltier effect-based temperature challenge: an improved method for diagnosing cold urticaria. J Allergy Clin Immunol (2004) 1.51
Basophils, eosinophils, and mast cells in atopic and nonatopic asthma and in late-phase allergic reactions in the lung and skin. J Allergy Clin Immunol (2000) 1.15
Upregulation of TNF-alpha and IL-3 expression in lesional and uninvolved skin in different types of urticaria. J Allergy Clin Immunol (1999) 1.01
Preclinical pharmacology of bilastine, a new selective histamine H1 receptor antagonist: receptor selectivity and in vitro antihistaminic activity. Drugs R D (2005) 1.00
What can microdialysis tell us about the temporal and spatial generation of cytokines in allergen-induced responses in human skin in vivo? J Invest Dermatol (2007) 0.99
Interactions of bilastine, a new oral H₁ antihistamine, with human transporter systems. Drug Chem Toxicol (2012) 0.99
An overview of bilastine metabolism during preclinical investigations. Drug Chem Toxicol (2012) 0.98
Acute and subchronic effects of bilastine (20 and 40 mg) and hydroxyzine (50 mg) on actual driving performance in healthy volunteers. J Psychopharmacol (2010) 0.97
Acquired cold urticaria: clinical picture and update on diagnosis and treatment. Clin Exp Dermatol (2007) 0.97
Lack of significant effect of bilastine administered at therapeutic and supratherapeutic doses and concomitantly with ketoconazole on ventricular repolarization: results of a thorough QT study (TQTS) with QT-concentration analysis. J Clin Pharmacol (2011) 0.95
Tear and conjunctival changes during the allergen-induced early- and late-phase responses. J Allergy Clin Immunol (2000) 0.95
Safety and efficacy of bilastine: a new H(1)-antihistamine for the treatment of allergic rhinoconjunctivitis and urticaria. Expert Opin Drug Saf (2011) 0.90
Effects of bilastine on T-wave morphology and the QTc interval: a randomized, double-blind, placebo-controlled, thorough QTc study. Clin Drug Investig (2012) 0.90
Microscopic morphology of different types of urticaria. Arch Dermatol (1998) 0.90
Rupatadine and its effects on symptom control, stimulation time, and temperature thresholds in patients with acquired cold urticaria. Ann Allergy Asthma Immunol (2010) 0.89
In vitro effects of H1-antihistamines on histamine and PGD2 release from mast cells of human lung, tonsil, and skin. Allergy (1994) 0.89
Basophil and eosinophil accumulation and mast cell degranulation in the nasal mucosa of patients with hay fever after local allergen provocation. J Allergy Clin Immunol (2000) 0.88
Effect of H1 receptor blockade on the early and late response to cutaneous allergen challenge. J Pharmacol Exp Ther (1992) 0.82
Antiallergic effects of H1-receptor antagonists. Allergy (2000) 0.81
Bilastine and the central nervous system. J Investig Allergol Clin Immunol (2011) 0.80
Critical temperature threshold measurement for cold urticaria: a randomized controlled trial of H(1) -antihistamine dose escalation. Br J Dermatol (2012) 0.80
Effects of loratadine on anti-IgE-induced inflammation, histamine release, and leukocyte recruitment in skin of atopics. Allergy (1995) 0.79
Whole-body tissue distribution of total radioactivity in rats after oral administration of [¹⁴C]-bilastine. Drug Chem Toxicol (2012) 0.78
The effect of cetirizine and loratadine on codeine-induced histamine release in human skin in vivo assessed by cutaneous microdialysis. Inflamm Res (1996) 0.78
Results and relevance of critical temperature threshold testing in patients with acquired cold urticaria. Br J Dermatol (2009) 0.78
Allergic Rhinitis and its Impact on Asthma (ARIA) 2008 update (in collaboration with the World Health Organization, GA(2)LEN and AllerGen). Allergy (2008) 12.35
Interleukin 21 and its receptor are involved in NK cell expansion and regulation of lymphocyte function. Nature (2000) 5.86
EAACI/GA(2)LEN/EDF/WAO guideline: definition, classification and diagnosis of urticaria. Allergy (2009) 4.10
EAACI/GA(2)LEN/EDF/WAO guideline: management of urticaria. Allergy (2009) 3.86
CENP-C, an autoantigen in scleroderma, is a component of the human inner kinetochore plate. Cell (1992) 3.70
Role of nonallergic hypersensitivity reactions in children with chronic urticaria. Allergy (1998) 3.20
The EAACI/GA(2) LEN/EDF/WAO Guideline for the definition, classification, diagnosis, and management of urticaria: the 2013 revision and update. Allergy (2014) 3.10
A comprehensive guide for the recognition and classification of distinct stages of hair follicle morphogenesis. J Invest Dermatol (1999) 2.92
Practical guide to skin prick tests in allergy to aeroallergens. Allergy (2011) 2.51
Unmet clinical needs in chronic spontaneous urticaria. A GA²LEN task force report. Allergy (2010) 2.34
Interleukin-8 concentrations are elevated in bronchoalveolar lavage, sputum, and sera of children with cystic fibrosis. Pediatr Res (1993) 2.22
Allergic Rhinitis and its Impact on Asthma (ARIA): achievements in 10 years and future needs. J Allergy Clin Immunol (2012) 2.17
Assessment of histamine-releasing activity of sera from patients with chronic urticaria showing positive autologous skin test on human basophils and mast cells. Clin Exp Allergy (2004) 2.13
Chronic rhinosinusitis in Europe--an underestimated disease. A GA²LEN study. Allergy (2011) 2.13
Home versus hospital deliveries: follow up study of matched pairs for procedures and outcome. Zurich Study Team. BMJ (1996) 2.10
Mast cells as sentinels of innate immunity. Curr Opin Immunol (1999) 1.85
Factors responsible for differences between asymptomatic subjects and patients presenting an IgE sensitization to allergens. A GA2LEN project. Allergy (2006) 1.84
Impaired mast cell-dependent natural immunity in complement C3-deficient mice. Nature (1997) 1.78
GA(2)LEN skin test study I: GA(2)LEN harmonization of skin prick testing: novel sensitization patterns for inhalant allergens in Europe. Allergy (2009) 1.72
A case-control study of the relation between plasma selenium and asthma in European populations: a GAL2EN project. Allergy (2008) 1.66
EAACI/GA(2)LEN task force consensus report: the autologous serum skin test in urticaria. Allergy (2009) 1.65
Autologous whole blood injections to patients with chronic urticaria and a positive autologous serum skin test: a placebo-controlled trial. Dermatology (2006) 1.65
Night-time sedating H1 -antihistamine increases daytime somnolence but not treatment efficacy in chronic spontaneous urticaria: a randomized controlled trial. Br J Dermatol (2014) 1.60
Human skin mast cells: their dispersion, purification, and secretory characterization. J Immunol (1987) 1.58
Molecular cloning, chromosome mapping and characterization of UBQLN3 a testis-specific gene that contains an ubiquitin-like domain. Gene (2000) 1.57
Insulin allergy: clinical manifestations and management strategies. Allergy (2008) 1.56
C3a and C5a stimulate chemotaxis of human mast cells. Blood (1997) 1.55
How to assess disease activity in patients with chronic urticaria? Allergy (2008) 1.55
EAACI/GA2LEN/EDF guideline: definition, classification and diagnosis of urticaria. Allergy (2006) 1.55
Proceedings: The inhibitory effect of insulin on pinnal anaphylaxis in the mouse. Br J Pharmacol (1974) 1.54
Embolization of biologic glue during repair of aortic dissection. Ann Thorac Surg (1995) 1.52
Mast cells. Int J Dermatol (1995) 1.52
How best to fight that nasty itch - from new insights into the neuroimmunological, neuroendocrine, and neurophysiological bases of pruritus to novel therapeutic approaches. Exp Dermatol (2005) 1.51
GA(2)LEN skin test study II: clinical relevance of inhalant allergen sensitizations in Europe. Allergy (2009) 1.51
Effects of a pseudoallergen-free diet on chronic spontaneous urticaria: a prospective trial. Allergy (2009) 1.49
Control of murine hair follicle regression (catagen) by TGF-beta1 in vivo. FASEB J (2000) 1.48
Allergen extract-induced interleukin-10 in human memory B cells inhibits immunoglobulin E production. Clin Exp Allergy (2009) 1.47
Food allergy and non-allergic food hypersensitivity in children and adolescents. Clin Exp Allergy (2004) 1.45
Viruses and bacteria in acute asthma exacerbations--a GA² LEN-DARE systematic review. Allergy (2010) 1.45
Characterization of histamine secretion from mechanically dispersed human lung mast cells: effects of anti-IgE, calcium ionophore A23187, compound 48/80, and basic polypeptides. J Immunol (1982) 1.45
Histamine release upon adenosine 5'-monophosphate (AMP) nasal provocation in allergic subjects. Thorax (1999) 1.43
A soluble class II cytokine receptor, IL-22RA2, is a naturally occurring IL-22 antagonist. Proc Natl Acad Sci U S A (2001) 1.43
Risk of first-generation H(1)-antihistamines: a GA(2)LEN position paper. Allergy (2010) 1.42
Immunoglobulin E decapeptide-induced 5-hydroxytryptamine release from rat peritoneal mast cells. Comparison with corticotropin-(1-24)-peptide, polyarginine, polylysine and antigen. Biochem J (1981) 1.41
H1-antihistamines: inverse agonism, anti-inflammatory actions and cardiac effects. Clin Exp Allergy (2002) 1.41
Fatal recurrent subarachnoid hemorrhage after complete endovascular aneurysm occlusion. AJNR Am J Neuroradiol (2006) 1.40
The definition and diagnostic testing of physical and cholinergic urticarias--EAACI/GA2LEN/EDF/UNEV consensus panel recommendations. Allergy (2009) 1.39
Adenosine inhibits and potentiates IgE-dependent histamine release from human lung mast cells by an A2-purinoceptor mediated mechanism. Biochem Pharmacol (1984) 1.38
Schnitzler's syndrome: diagnosis, treatment, and follow-up. Allergy (2013) 1.35
NMR solution structure of a complex of calmodulin with a binding peptide of the Ca2+ pump. Biochemistry (1999) 1.33
Inhibition profiles of sodium cromoglycate and nedocromil sodium on mediator release from mast cells of human skin, lung, tonsil, adenoid and intestine. Clin Exp Allergy (1992) 1.32
Identification of a novel class of genomic DNA-binding sites suggests a mechanism for selectivity in target gene activation by the tumor suppressor protein p53. Genes Dev (1998) 1.31
Adenosine inhibits and potentiates IgE-dependent histamine release from human basophils by an A2-receptor mediated mechanism. Br J Pharmacol (1983) 1.29
p53 is essential for chemotherapy-induced hair loss. Cancer Res (2000) 1.29
EAACI/GA2LEN/EDF guideline: management of urticaria. Allergy (2006) 1.28
Melanogenesis during the anagen-catagen-telogen transformation of the murine hair cycle. J Invest Dermatol (1994) 1.27
The inhibition by dexamethasone and disodium cromoglycate of anaphylactic bronchoconstriction in the rat. Br J Pharmacol (1972) 1.27
Human mast cell heterogeneity: histamine release from mast cells dispersed from skin, lung, adenoids, tonsils, and colon in response to IgE-dependent and nonimmunologic stimuli. J Allergy Clin Immunol (1988) 1.27
Complement peptides C3a- and C5a-induced mediator release from dissociated human skin mast cells. J Invest Dermatol (1994) 1.27
A simultaneous (15)N, (1)H- and (13)C, (1)H-HSQC with sensitivity enhancement and a heteronuclear gradient echo. J Biomol NMR (1995) 1.25
Influence of albuterol, cromolyn sodium and ipratropium bromide on the airway and circulating mediator responses to allergen bronchial provocation in asthma. Am Rev Respir Dis (1985) 1.25
Impaired mast cell development and innate immunity in Mac-1 (CD11b/CD18, CR3)-deficient mice. J Immunol (1998) 1.25
Standard skin prick testing and sensitization to inhalant allergens across Europe--a survey from the GALEN network. Allergy (2005) 1.25
Quality of life in patients with chronic urticaria is differentially impaired and determined by psychiatric comorbidity. Br J Dermatol (2006) 1.24
Development and implementation of guidelines in allergic rhinitis – an ARIA-GA2LEN paper. Allergy (2010) 1.24
Early and late-phase bronchoconstriction after allergen challenge of nonanesthetized guinea pigs. I. The association of disordered airway physiology to leukocyte infiltration. Am Rev Respir Dis (1988) 1.24
Inhibition of IgE-dependent histamine release from human dispersed lung mast cells by anti-allergic drugs and salbutamol. Br J Pharmacol (1987) 1.24
Inhibition of histamine release from human lung in vitro by antihistamines and related drugs. Br J Pharmacol (1980) 1.23
Allergic rhinitis management pocket reference 2008. Allergy (2008) 1.23
MeDALL (Mechanisms of the Development of ALLergy): an integrated approach from phenotypes to systems medicine. Allergy (2011) 1.22
GA2LEN (Global Allergy and Asthma European Network) addresses the allergy and asthma 'epidemic'. Allergy (2009) 1.22
Tumour necrosis factor alpha: a potential mediator of asthma. Clin Exp Allergy (1995) 1.21
Characterization of functional vanilloid receptors expressed by mast cells. Blood (1998) 1.21
Important research questions in allergy and related diseases: nonallergic rhinitis: a GA2LEN paper. Allergy (2008) 1.20
p53 Involvement in the control of murine hair follicle regression. Am J Pathol (2001) 1.19
Immunohistochemical identification of mast cells in formaldehyde-fixed tissue using monoclonal antibodies specific for tryptase. J Pathol (1990) 1.17
Undertreatment of rhinitis symptoms in Europe: findings from a cross-sectional questionnaire survey. Allergy (2007) 1.16
Methods report on the development of the 2013 revision and update of the EAACI/GA2 LEN/EDF/WAO guideline for the definition, classification, diagnosis, and management of urticaria. Allergy (2014) 1.16
Effect of a thromboxane receptor antagonist on PGD2- and allergen-induced bronchoconstriction. J Appl Physiol (1985) (1989) 1.16
Heterogeneity of human mast cells based on cytokine content. J Immunol (1995) 1.15
Re-engineering the toilet for sustainable waste water management. Environ Sci Technol (2001) 1.14
Rupatadine in allergic rhinitis and chronic urticaria. Allergy (2008) 1.13
Epidemiology of urticaria: a representative cross-sectional population survey. Clin Exp Dermatol (2010) 1.12
The relationship between cyclic AMP changes and histamine release from basophil-rich human leucocytes. Biochem Pharmacol (1983) 1.12
Human mast cells express stem cell factor. J Pathol (1998) 1.12
Antibacterial effects of cefroxadine, cephalexin and cephradine in a new in vitro pharmacokinetic model. J Antibiot (Tokyo) (1982) 1.11
Response of rat lung to humoral mediators of anaphylaxis and its modification by drugs and sensitization. Br J Pharmacol (1975) 1.10
Role of nasal interleukin-8 in neutrophil recruitment and activation in children with virus-induced asthma. Am J Respir Crit Care Med (1997) 1.10